205 related articles for article (PubMed ID: 35070747)
1. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.
Wang Z; Wei L; Li J; Zhou H; Li S; Chen D; Yu Y; Zhao L; Zhu X; Song Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4368-4379. PubMed ID: 35070747
[TBL] [Abstract][Full Text] [Related]
2. Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Xu Y; Li H; Fan Y
Front Oncol; 2021; 11():642883. PubMed ID: 33747966
[TBL] [Abstract][Full Text] [Related]
3. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
Joosten PJM; de Langen AJ; van der Noort V; Monkhorst K; Klomp HM; Veenhof AAFA; Dickhoff C; Smit EF; Hartemink KJ
Lung Cancer; 2021 Nov; 161():141-151. PubMed ID: 34600405
[TBL] [Abstract][Full Text] [Related]
4. Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.
Sindhu KK; Leiter A; Moshier E; Lin JY; Carroll E; Brooks D; Shimol JB; Eisenberg E; Gallagher EJ; Stock RG; Galsky MD; Buckstein M
Cancer Treat Res Commun; 2020; 25():100216. PubMed ID: 33049542
[TBL] [Abstract][Full Text] [Related]
5. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy prolongs the progression-free survival and delays the change of systemic therapy regimen in patients with lung oligoprogressive metastatic colorectal cancer.
Li S; Dong D; Geng J; Zhu X; Shi C; Zhang Y; Wang H; Zhou S; Wu H; Cai Y; Li Y; Wang W
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e64-e72. PubMed ID: 33629479
[TBL] [Abstract][Full Text] [Related]
7. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.
Ebadi M; Ladbury C; Liu J; Rock A; Onyshchenko M; Villaflor V; Villalona-Calero M; Salgia R; Massarelli E; Lee P; Williams T; Amini A
Clin Lung Cancer; 2023 Nov; 24(7):651-659. PubMed ID: 37714807
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer.
Li S; Dong D; Geng J; Zhu X; Shi C; Zhang Y; Wang H; Zhou S; Wu H; Cai Y; Li Y; Wang W
Front Oncol; 2019; 9():1080. PubMed ID: 31681609
[No Abstract] [Full Text] [Related]
10. Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer.
Levy A; Khalifa J; Martin E; Botticella A; Quevrin C; Lavaud P; Aldea M; Besse B; Planchard D; Barlesi F; Deutsch E; Massabeau C; Doyen J; Le Péchoux C
Clin Transl Radiat Oncol; 2023 Jul; 41():100637. PubMed ID: 37206411
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy.
Tsur E; Blumenfeld P; Rottenberg Y; Nechushtan H; Arnon J; Wald O; Izhar U; Pfeffer R; Krakow A; Wygoda M; Popovtzer A; Michaeli TF
Transl Lung Cancer Res; 2024 Mar; 13(3):465-474. PubMed ID: 38601442
[TBL] [Abstract][Full Text] [Related]
13.
Bahig H; Tonneau M; Blais N; Wong P; Filion E; Campeau MP; Vu T; Al-Saleh A; Tehfé M; Florescu M; Roberge D; Masucci L; Richard C; Menard C; Routy B
Clin Transl Radiat Oncol; 2022 Mar; 33():115-119. PubMed ID: 35243022
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters.
Tan H; Cheung P; Louie AV; Myrehaug S; Niglas M; Atenafu EG; Chu W; Chung HT; Poon I; Sahgal A; Soliman H
Radiother Oncol; 2021 Aug; 161():159-165. PubMed ID: 34119585
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial.
Spaas M; Sundahl N; Hulstaert E; Kruse V; Rottey S; De Maeseneer D; Surmont V; Meireson A; Brochez L; Reynders D; Goetghebeur E; Van den Begin R; Van Gestel D; Renard V; Dirix P; Mestdagh P; Ost P
BMC Cancer; 2021 May; 21(1):514. PubMed ID: 33962592
[TBL] [Abstract][Full Text] [Related]
16. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
Merino Lara T; Helou J; Poon I; Sahgal A; Chung HT; Chu W; Soliman H; Ung Y; Verma S; Cheema P; Cheng S; Khanna S; Erler D; Zhang L; Cheung P
Lung Cancer; 2018 Oct; 124():219-226. PubMed ID: 30268464
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
Clin Transl Radiat Oncol; 2024 Mar; 45():100748. PubMed ID: 38433950
[TBL] [Abstract][Full Text] [Related]
19. A real-world analysis of stereotactic body radiotherapy combined with immunotherapy in advanced or recurrent non-small cell lung cancer (NSCLC): A single-center experience.
Yao D; Zhu X; Guo J; Dong X; Zeng Y; Fu X; Yu W
Clin Transl Radiat Oncol; 2024 Jul; 47():100787. PubMed ID: 38770061
[TBL] [Abstract][Full Text] [Related]
20. Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis.
Comito F; Leslie I; Boos L; Furness A; Pickering L; Turajlic S; Larkin J
J Immunother; 2020 Oct; 43(8):250-255. PubMed ID: 32796274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
